Bladder cancer
Not yet recruitingStudy of Sacituzumab Govitecan and Zimberelimab for Muscle-Invasive Bladder Cancer in Patients Unable to Take Cisplatin or Unwilling to Have Surgery
Study of Sacituzumab Govitecan and Zimberelimab for Muscle-Invasive Bladder Cancer in Patients Unable to Take Cisplatin or Unwilling to Have Surgery
- Disease:Bladder cancer
- Substances:ZimberelimabSacituzumab Govitecan
Italy- Participants:18–64 years · 65+ years
- Substances:Zimberelimab
- Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori








